(Q37827167)

23 August 2017

1 reference

title

Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010. (English)

1 reference

23 August 2017

Inder Pal Singh

1

1 reference

23 August 2017

Siddheshwar K Chauthe

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 January 2011

1 reference

Expert Opinion on Therapeutic Patents

23 August 2017

published in

1 reference

23 August 2017

volume

21

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

227-269

1 reference

HIV-1 integrase inhibitors: 2005-2006 update

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Drug interactions in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Chemokine receptor antagonists: Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Chemokine receptor antagonists: part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Recent patents regarding the discovery of small molecule CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

CD4 down-modulating compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Microbicide drug candidates to prevent HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Safe use of the CXCR4 inhibitor ALX40-4C in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Structure-activity relationships of an anti-HIV peptide, T22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

Entry and fusion inhibitors of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.542412

10.1517/13543776.2011.542412

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference